Pharmaceuticals company Jubilant Pharmova announced Q1FY26 results Revenue from Operations rose by 10% YoY, from Rs 1,732 crore to Rs 1,901 crore Total Income increased by 10% YoY, from Rs 1,746 crore to Rs 1,913 crore EBITDA grew by 14% YoY, from Rs 266 crore to Rs 302 crore due to improved performance in CRDMO and Generics. EBITDA Margin improved by 60 bps, from 15.2% to 15.8% Normalised PAT jumped 48% YoY, from Rs 69 crore to Rs 103 crore Normalised PAT Margin expanded by 140 bps, from 4.0% to 5.4% Reported PAT in Q1’FY25 at Rs 482 Cr. was higher because of one time exceptional income of Rs 396 Cr. Shyam S Bhartia, Chairman Jubilant Pharmova and Mr. Hari S Bhartia, Co-Chairman & Non-Executive Director, Jubilant Pharmova said, “We are pleased to announce revenue of Rs 1,901 crore. in Q1’FY26, growth of 10% over last year, same quarter. It is heartening to note is that we delivered solid revenue growth across all of our business units and we expect this growth momentum to grow stronger as we move forward. EBITDA grew by 14% YoY to Rs 302 crore. Ebitda margins expanded by 60 basis points on the back of improved operating performance across CRDMO and Generics. Normalised PAT grew by 48% to Rs 103 crore. on the back of improved operating performance and reduced finance cost. Reported PAT in Q1FY25 at Rs 482 crore. was higher because of one time net exceptional income of Rs 396 crore. As we are consciously investing in Radiopharma, CDMO Sterile Injectables and CRDMO business to secure future growth, Net Debt / EBITDA increased marginally from 1.1x in Mar’25 to 1.2x in Jun’25 on the back of increased capex intensity. During Q1’FY26, we saw continued growth momentum from Ruby-Fill® and PET radiopharmacies. In the Allergy Immunotherapy, we witnessed increase in demand from the US. In the CDMO Sterile Injectables, strong customer traction for Line 3 in Spokane continues. In the CRDMO business, we integrated the new R&D; facility in France and are now investing in business development initiatives. In the Generics business, we are foreseeing growth & profitability improvement. Lastly, in our Proprietary Novel drugs business, we continue to progress in dosing patients in JBI-802 and JBI-778 clinical trials.” Result PDF